Strong Execution and Operational Transformation in 2024 Delivered Record Full Year Results and Provides Momentum for Double-Digit Revenue and Profitability Growth in 2025 4Q 2024 Total Revenues of $747 million (+16% Y/Y and +21% at […]
Tag: BioMarin Pharmaceutical Inc.
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024
SAN RAFAEL, Calif., Nov. 16, 2024 /PRNewswire/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive and consistent results from multiple real-world evidence studies of VOXZOGO® (vosoritide) in children with achondroplasia. These results, as well as data […]
BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance
NEW YORK, Sept. 4, 2024 /PRNewswire/ — BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) hosted an Investor Day earlier today, where President and Chief Executive Officer Alexander Hardy and other members of BioMarin’s leadership team provided an […]